SINGAPORE — Peptobiotics, a pioneering biotech startup, has successfully secured $6.2 million in Series A funding to further develop and commercialize its innovative antimicrobial peptide technology, which aims to replace antibiotics in agriculture, particularly in the aquaculture industry.
The funding round, led by Hatch’s Blue Revolution Fund, was notably oversubscribed, reflecting strong investor interest.
This investment will enable Peptobiotics to scale up production and advance its technology, which has already shown promise in international trials, in addressing bacterial infections in aquaculture without the use of traditional antibiotics.
Such infections are a major cost burden to shrimp farmers globally.
Peptobiotics’ technology focuses on harnessing naturally occurring peptides that combat bacteria effectively without contributing to the growing issue of antibiotic resistance.
This breakthrough could significantly impact the way diseases are managed in aquaculture, supporting more sustainable and environmentally friendly farming practices.
“Our breakthrough was screening through the 1000s of peptides to find the ones that could have real efficacy in agriculture, then figuring out the biotechnology innovations needed to produce them on an industrial scale at a price point acceptable to our customers,” said Koh Jhee Hong, Co-Founder & CTO of Peptobiotics
The round also saw participation from major agritech investors including Seventure Partners and SEEDS Capital, among others, indicating a strong support for Peptobiotics’ mission to provide a viable, effective alternative to antibiotics in the agricultural sector.
PEVCJournal.com